E-Mail
IMAGE: The overall relationship between spiritual fitness and a person s complete physical and mental health. view more
Credit: Dr. Khalsa and Dr. Newberg
Amsterdam, May 11, 2021 - It is projected that up to 152 million people worldwide will be living with Alzheimer s disease (AD) by 2050. To date there are no drugs that have a substantial positive impact on either the prevention or reversal of cognitive decline. A growing body of evidence finds that targeting lifestyle and vascular risk factors have a beneficial effect on overall cognitive performance. A new review in the
Journal of Alzheimer s Disease, published by IOS Press, examines research that finds spiritual fitness, a new concept in medicine that centers on psychological and spiritual wellbeing, and Kirtan Kriya, a simple 12-minute meditative practice, may reduce multiple risk factors for AD.
Spiritual fitness and meditative practice may reduce multiple risk factors for Alzheimer s disease
It is projected that up to 152 million people worldwide will be living with Alzheimer s disease (AD) by 2050. To date there are no drugs that have a substantial positive impact on either the prevention or reversal of cognitive decline. A growing body of evidence finds that targeting lifestyle and vascular risk factors have a beneficial effect on overall cognitive performance. A new review in the
Journal of Alzheimer s Disease, published by IOS Press, examines research that finds spiritual fitness, a new concept in medicine that centers on psychological and spiritual wellbeing, and Kirtan Kriya, a simple 12-minute meditative practice, may reduce multiple risk factors for AD.
NervGen Pharma Corp.: NervGen Pharma Reports 2020 Year End Results
Vancouver, British Columbia (Newsfile Corp. - April 8, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today reported its financial results for the year ended December 31, 2020.
Paul Brennan, NervGen s President & CEO, stated, We made substantial progress in the development of our lead program, NVG-291, towards clinical trials during 2020. We were able to resubmit our Investigational New Drug Application for NVG-291 early in 2021 and we look forward to starting our Phase 1 trial in Australia this quarter. We continue to generate encouraging preclinical data to support our programs to bring life-changing hope to many people suffering from nerve damage as a result of injury or neurodegenerative diseases. Pending successful completion of our Phase 1 stud
NervGen Pharma Corp.: NervGen Pharma Establishes Alzheimer s Disease Scientific Advisory Board
Vancouver, British Columbia (Newsfile Corp. - January 26, 2021) -
NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ( NervGen or the Company ), a biotech company dedicated to creating innovative solutions for the treatment of nerve damage and neurodegenerative diseases, today announced the formation of its Alzheimer s Disease Scientific Advisory Board ( AD-SAB ) with the appointment of four world-class scientists and clinical researchers in Alzheimer s disease: Jeffrey Cummings, MD, ScD; George Perry, PhD; Henrik Zetterberg, MD, PhD; and Bruce Lamb, PhD. The AD-SAB will work closely with NervGen as the Company plans its upcoming preclinical studies and clinical trials and in the analyses of the results from these studies.